Strongbridge Biopharma plc.
SBBP
SBBP was delisted on the 5th of October, 2021.
58 hedge funds and large institutions have $49.7M invested in Strongbridge Biopharma plc. in 2019 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 24 increasing their positions, 10 reducing their positions, and 11 closing their positions.
140% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 10
36% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 11
7% more funds holding
Funds holding: 54 → 58 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
23% less capital invested
Capital invested by funds: $64.8M → $49.7M (-$15.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.9M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$1.15M |
| 3 |
Renaissance Technologies
New York
|
+$834K |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$828K |
| 5 |
DT
Diversified Trust
Memphis,
Tennessee
|
+$381K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$6.16M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
-$2.41M |
| 3 |
2L
22NW LP
Seattle,
Washington
|
-$1.92M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.17M |
| 5 |
BlackRock
New York
|
-$1.02M |
SBBP Hedge Fund Activity: Q4 2019 in Review
58 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q4 2019, worth a combined $49.7M — down 23% from $64.8M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new SBBP positions and 11 closed out — a net gain of 4 holders — while 24 added to existing stakes and 10 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.9M. The largest seller was Broadfin Capital, exiting entirely with an estimated $6.16M sold.
- 58 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q4 2019, up from 54 in Q3 2019.
- Funds reported $49.7M of Strongbridge Biopharma plc. stock for Q4 2019, down 23% quarter-over-quarter.
- 15 funds opened new Strongbridge Biopharma plc. positions in Q4 2019 and 11 closed out, a net change of +4 holders.
- The largest Strongbridge Biopharma plc. buyer in Q4 2019 was Vanguard Group, an estimated $1.9M added.
- The largest Strongbridge Biopharma plc. seller in Q4 2019 was Broadfin Capital, an estimated $6.16M sold.
Based on aggregated 13F filings for Q4 2019.